-
公开(公告)号：US20090208945A1
公开(公告)日：2009-08-20
申请号：US12097961
申请日：2006-12-19
申请人： Stephan Schwers , Udo Stropp , Harald Kallabis , Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Gerd Schmitz
发明人： Stephan Schwers , Udo Stropp , Harald Kallabis , Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Gerd Schmitz
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/42 , C12Q1/50 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172 , G01N33/92
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a SADR gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat statin induced adverse drug reactions (SADR), the polynucleotide is selected from the group comprising: SEQ ID 1-35 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for SADR gene polypeptide and with or without the SADR gene promoter sequence.
摘要翻译： 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否存在药物反应不利的风险的抗体。 本发明还提供了多态序列和其他基因。 本发明还涉及编码SADR基因多肽的分离的多核苷酸，其用于鉴定治疗剂并可用于制备治疗他汀类药物诱导的不良药物反应（SADR）的药物的方法中，所述多核苷酸选自SEQ ID No.1 -35具有等位基因变异，如包含在功能性周围的序列部分中所示，如SADR基因多肽的全长cDNA并具有或不具有SADR基因启动子序列。
-
公开(公告)号：US20090093689A1
公开(公告)日：2009-04-09
申请号：US12158744
申请日：2006-12-11
申请人： Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Stephan Schwers , Udo Stropp , Harald Kallabis
发明人： Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Stephan Schwers , Udo Stropp , Harald Kallabis
摘要： The invention relates to a method for developing a biomarker for the prognosis of the result of a therapeutical treatment based on data obtained in clinical studies, data remaining unchanged by therapy being subdivided into diagnostic and genomic parameters and the marker being defined by a combination of parameters. The method according to the invention is characterized by specifying the maximum number of parameters for defining the marker and thus the maximum complexity of the system from the beginning and by carrying out the search for defining parameters by sequential combination of clinical parameters (=z parameters) and/or genomic parameters (=x parameters).
摘要翻译： 本发明涉及一种基于临床研究中获得的数据，用于预测治疗结果的预后的生物标志物的方法，通过治疗将其保持不变的数据被细分为诊断和基因组参数，并且所述标记由参数的组合定义 。 根据本发明的方法的特征在于指定用于定义标记的参数的最大数目，并且因此指定从一开始的系统的最大复杂度，并且通过临时参数（= z参数）的顺序组合执行定义参数的搜索， 和/或基因组参数（= x参数）。
-
公开(公告)号：US08355874B2
公开(公告)日：2013-01-15
申请号：US12158744
申请日：2006-12-11
申请人： Andreas Schuppert , Rolf Burghaus , Christian Von Törne , Stephan Schwers , Udo Stropp , Harald Kallabis
发明人： Andreas Schuppert , Rolf Burghaus , Christian Von Törne , Stephan Schwers , Udo Stropp , Harald Kallabis
IPC分类号： G01N33/48
摘要： The invention relates to a method for developing a biomarker for the prognosis of the result of a therapeutical treatment based on data obtained in clinical studies, data remaining unchanged by therapy being subdivided into diagnostic and genomic parameters and the marker being defined by a combination of parameters. The method according to the invention is characterized by specifying the maximum number of parameters for defining the marker and thus the maximum complexity of the system from the beginning and by carrying out the search for defining parameters by sequential combination of clinical parameters (=z parameters) and/or genomic parameters (=x parameters).
摘要翻译： 本发明涉及一种基于临床研究中获得的数据，用于预测治疗结果预后的生物标志物的方法，通过治疗将其保持不变的数据被细分为诊断和基因组参数，并且所述标记由参数组合定义 。 根据本发明的方法的特征在于指定用于定义标记的参数的最大数目，并且因此指定从一开始的系统的最大复杂度，并且通过临时参数（= z参数）的顺序组合执行定义参数的搜索， 和/或基因组参数（= x参数）。
-
公开(公告)号：US20050197986A1
公开(公告)日：2005-09-08
申请号：US10511231
申请日：2003-04-02
申请人： Andreas Schuppert , Arne Ohrenberg
发明人： Andreas Schuppert , Arne Ohrenberg
CPC分类号： G05B13/0205 , G05B15/02
摘要： Method and system for designing experiments by selecting at least a first experiment from an experimental space using a data-driven optimizer, receiving experimentally determined data, evaluating the experimentally determined data at a mata layer module, processing the experimentally determined data at the optimizer; the processing at the optimizer being influenced by the evaluation data.
摘要翻译： 通过使用数据驱动的优化器从实验空间中选择至少第一个实验来设计实验的方法和系统，接收实验确定的数据，在mata层模块评估实验确定的数据，在优化器处理实验确定的数据; 优化器处理受到评估数据的影响。
-
5.发明申请公开(公告)号：US20090326897A1
公开(公告)日：2009-12-31
申请号：US12307987
申请日：2007-06-28
摘要： The invention relates to a method for determining the behavior of at least one biological system after a reversible perturbation, comprising the following steps: (a) providing at least one biological system, the biological system comprising a biological network comprising a multiplicity of biological or biochemical components, which have an activity; (b) providing a linear model for describing the behavior of the network of the biological system; (c) determining the activity of the biological or biochemical components of the biological network; (d) reversibly perturbing the activity of at least one of the biological or biochemical components, a reaction of the biological network being generated which is formed by the change in the activity of at least one or more of the biological or biochemical components; (e) determining the activity of the biological or biochemical components of the biological network after exerting the reversible perturbation, as soon as the components of the network have completed the reaction to the perturbation; (f) determining the change in the activity of at least one biological or biochemical component of the biological network as a reaction to the reversible perturbation; (g) calculating the behavior of the biological network with the aid of the linear model provided for describing the behavior of the biological network and the change in the activity of the biological or biochemical component(s) of the biological network after the reversible perturbation as determined in step (f), while taking into account the biodiversity of the reaction of the biological or biochemical component(s); and (h) optionally comparison between the change in the activity of the individual components as determined according to step (f) and the behavior of the biological network as calculated according to step (g) with the aid of the linear model which is provided, there being expected to be a match of the calculated behavior with the change in the activity of the biological or biochemical component(s) as determined in step (f).
-
公开(公告)号：US20070253903A1
公开(公告)日：2007-11-01
申请号：US11569449
申请日：2005-05-14
申请人： Bernhard Knab , Jorg Lippert , Roland Loosen , Andreas Schuppert , Michael Sevestre , Juri Solodenko , Stefan Willmann
发明人： Bernhard Knab , Jorg Lippert , Roland Loosen , Andreas Schuppert , Michael Sevestre , Juri Solodenko , Stefan Willmann
IPC分类号： A61K49/00
CPC分类号： G16C20/30
摘要： The invention relates to a method for dosing specific doses and timed dosage profiles of medicaments (in animals and humans) as well as agrochemicals (for the treatment of plants).
摘要翻译： 本发明涉及药物（动物和人类）以及农用化学品（用于处理植物）的特定剂量和定时剂量曲线的方法。
-
公开(公告)号：US07424465B2
公开(公告)日：2008-09-09
申请号：US10511231
申请日：2003-04-02
申请人： Andreas Schuppert , Arne Ohrenberg
发明人： Andreas Schuppert , Arne Ohrenberg
CPC分类号： G05B13/0205 , G05B15/02
摘要： Method and system for designing experiments by selecting at least a first experiment from an experimental space using a data-driven optimizer, receiving experimentally determined data, evaluating the experimentally determined data at a mata layer module, processing the experimentally determined data at the optimizer; the processing at the optimizer being influenced by the evaluation data.
摘要翻译： 通过使用数据驱动的优化器从实验空间中选择至少第一个实验来设计实验的方法和系统，接收实验确定的数据，在mata层模块评估实验确定的数据，在优化器处理实验确定的数据; 优化器处理受到评估数据的影响。
-
公开(公告)号：US20050038607A1
公开(公告)日：2005-02-17
申请号：US10494845
申请日：2002-11-11
申请人： Andreas Schuppert
发明人： Andreas Schuppert
CPC分类号： G01N33/6803
摘要： The present invention relates to a method for identifying a molecular pharmacophore, generally comprising the following steps: inputting descriptors of chemical compounds, and assigning effects or results (Rp) of each descriptor. Each descriptor comprises a number of variables (V1, V2, . . . , Vn). Both binary and ternary variations of the variables are determined, and the binary variations are assigned to an active entity of a putative pharmacophore. Variable pair candidates from the ternary variations are determined for assignment to a common active entity, the common active entity having two or more variables, and further determining a set of variables for each variable pair candidate which contains such variables, which, when the variable pair candidate is assigned to the common active entity, have to be assigned to an active entity other than the common active entity. Conflict-free clusters of sets of variables are used to identify one or more common active entities.
摘要翻译： 本发明涉及一种鉴定分子药效团的方法，通常包括以下步骤：输入化合物的描述符，并分配每个描述符的效应或结果（R p）。 每个描述符包括多个变量（V1，V2，...，Vn）。 确定变量的二进制和三元变量，并将二进制变量分配给推定的药效团的活性实体。 确定来自三元变化的可变对候选者用于分配给共同活动实体，公共活动实体具有两个或多个变量，并进一步确定包含这些变量的每个可变对候选者的一组变量，当变量对 候选人被分配给公共活动实体，必须分配给除了公共活动实体之外的活动实体。 使用无冲突的变量集合来识别一个或多个常见的活动实体。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.03 秒)
